ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2029

Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis
Abstract Number: 0741

Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
Abstract Number: 2001

Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
Abstract Number: 1109

Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Abstract Number: 1386

Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
Abstract Number: 2070

Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
Abstract Number: 1999

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Abstract Number: 1064

Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
Abstract Number: 1628

Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Abstract Number: 1437

Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
Abstract Number: 0752

Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Abstract Number: 0470

Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Abstract Number: 0008

Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Abstract Number: 1693

Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Abstract Number: 0629

Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].